Zyversa therapeutics ceo issues shareholder letter announcing transformative r&d trends for inflammasome inhibitors, and provides update on inflammasome asc inhibitor ic 100's development status

Inflammasome inhibitors have moved into p2 trials based on preclinical/p1 safety data & promising signals of efficacy. data read-outs expected beginning h1
ASC Ratings Summary
ASC Quant Ranking